2.20

1.85% 0.04

After Hours: 2.20

Cardiol Therapeutics Inc (CRDL)

Overview News Price History Option Chain Why CRDL Down? Discussions Forecast

Cardiol Therapeutics Inc stock is traded at $2.20, with a volume of 1.05M. It is up +1.85% in the last 24 hours and up +61.76% over the past month. Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Previous Close:

$2.16

Open:

$2.16

24h Volume:

1.05M

Relative Volume:

1.09

Market Cap:

$257.01M

Revenue:

Net Income/Loss:

$-26.33M

P/E Ratio:

-7.7904

EPS:

-0.2824

Net Cash Flow:

$-17.65M

1W Performance:

+13.40%

1M Performance:

+61.76%

6M Performance:

+115.69%

1Y Performance:

+98.20%

1-Day Range:

$2.12

$2.2191

1-Week Range:

$1.88

$2.235

52-Week Range:

$0.88

$2.275

Cardiol Therapeutics Inc Stock (CRDL) Company Profile

Name

Cardiol Therapeutics Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

CRDL's Discussions on Twitter

Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDL Cardiol Therapeutics Inc	2.20	220.21M	0	-26.33M	-17.65M	-0.2824
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Initiated	H.C. Wainwright	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jun-26-24	Initiated	ROTH MKM	Buy
Apr-22-24	Initiated	H.C. Wainwright	Buy

Cardiol Therapeutics Inc Stock (CRDL) Latest News

Sep 02, 2026

Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca

Sep 02, 2026

Aug 31, 2026

Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca

Aug 31, 2026

Aug 28, 2026

Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 28, 2026

Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca

Aug 28, 2026

Aug 27, 2026

Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research

Aug 27, 2026

Cardiol Therapeutics Inc. (TSX:CRDL) Gains Momentum as Clinical Pipeline Progress and Heart Disease Therapies Drive Investor Optimism - kalkine.ca

Aug 27, 2026

Aug 26, 2026

B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com Canada

Aug 26, 2026

Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress - kalkine.ca

Aug 26, 2026

Aug 25, 2026

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Aug 25, 2026

Aug 24, 2026